Hormonal
Obesity superimposed on aging exacerbates chronic low-grade inflammation (inflammaging), which drives insulin resistance and increases the risk of age-related diseases such as type-2 diabetes, rheumatoid arthritis, and cognitive impairment.
If you are older and carrying extra weight, your body is likely in a state of chronic, low-grade inflammation that increases your risk for diabetes, heart disease, and cognitive decline. This isn't just about appearance; it's a biological process. Managing this risk involves addressing the underlying inflammation and metabolic health, not just weight loss alone.
Obesity superimposed on aging drastically increases chronic low-grade inflammation (inflammaging), which is an important link between obesity, insulin resistance, and age-associated diseases.
Why this rating
This is a mini-review citing multiple primary studies and meta-analyses, establishing a strong consensus on the mechanistic link.
Source
Aging, Obesity, and Inflammatory Age-Related Diseases
Daniela Frasca et al. · Frontiers in Immunology · 2017
DOI 10.3389/fimmu.2017.01745
More from this paper
- Obesity negatively impacts the response to therapy in Rheumatoid Arthritis (RA), reducing the likelihood of achieving sustained remission with both conventional and biologic agents.Good
- Mid-life obesity is associated with an increased risk of dementia and Alzheimer's disease later in life, whereas late-life obesity may show a paradoxical protective effect or no increased risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →